Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-I improves risk stratification

Thrombosis and Haemostasis

Volumn 93, Issue 3, 2005, Pages 559-563

  Silvestro, Antonio ^a,b   Brevetti, Gregorio ^a   Shiano, Vittorio ^a   Scopacasa, Francesco ^a   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b University Federico II ^*  (Italy)

Author keywords

Adhesion molecules; Cardiovascular diseases; Peripheral arterial disease; Prognosis; Risk prediction

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM ANTAGONIST; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; NITRATE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RISK ASSESSMENT;

AGED; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK; SOLUBILITY; VASCULAR CELL ADHESION MOLECULE-1;

EID: 15344344485     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-07-0440     Document Type: Article

References (36)

1. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
2. Cybulsky M, Gimbrone M. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-91.
3. Iiyama K, Hajra L, Iiyama M, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999; 85: 199-207.
4. Davies M, Gordon J, Gearing A, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993; 171: 223-9.
5. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
7. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-42.
8. Mulvihill NT, Foley JB, Murphy RT, et al. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001; 85: 623-7.
9. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-4.
10. Brevetti G, Martone VD, de Cristofaro T, et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost 2001; 85: 63-6.
11. Brevetti G, Piscione F, Silvestro A, et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost 2003; 89: 1058-63.
12. Blann AD, Seigneur M, Steiner M, et al. Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolemia: relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events. Thromb Haemost 1998; 79: 1080-5.
13. Brevetti G, Martone V, Perna S, et al. Intermittent claudication and risk of cardiovascular event. Angiology 1998; 49: 843-8.
14. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-6.
15. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119-28.
16. Peter K, Nawroth P, Conradt C, et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505-12.
17. Silvestro A, Scopacasa F, Ruocco A, et al. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med 2003; 8: 225-32.
18. Brevetti G, Silvestro A, Schiano V, et al. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108: 2093-8.
19. Newman A, Sutton-Tyrrell K, Vogt M, et al. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 1993; 270: 487-9.
20. Cox D. Regression and life tables. J R Stat Soc 1972; 34: 187-220.
21. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-12.
22. Ohta T, Saku K, Takata K, et al. Soluble vascular cell-adhesion molecule-1 and soluble intercellular adhesion molecule-1 correlate with lipid and apolipoprotein risk factors for coronary artery disease in children. Eur J Pediatr 1999; 158: 592-8.
23. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
24. O'Brien KD, McDonald TO, Chait A, et al. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672-82.
25. Li H, Cybulsky M, Gimbrone MJ, et al. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leucocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993; 13: 197-204.
26. O'Riordain D, O'Donnell J. Realistic expectations for the patient with intermittent claudication. Br J Surg 1991; 78: 861-2.
27. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994; 1: 333-9.
28. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106: 820-5.
29. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-9.
30. Maresca G, Di Blasio A, Marchioli R, et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-77.
31. Gokce N, Keaney JF, Jr., Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41: 1769-75.
32. Rasmussen L, Hansen P, Nabipour M, et al. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J 2001; 360: 363-70.
33. Cominacini L, Pasini A, Garbin U, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15: 891-5.
34. Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J 2003; 146: 218-26.
35. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
36. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.